Can the role of Africa Vaccine Manufacturers Initiative include coordination of the HIV Vaccine research and development enterprise in Africa?

By Morenike Oluwatoyin Folayan

At the just concluded Africa Vaccine Manufacturers Initiative (AVMI) meeting held at the Radisson Hotel at Freetown, Sierra Leone on the 24th and 25th of September, 2018, the suggestion for AVMI to coordinate the HIV vaccine research and development enterprise on the continent was muted. The role of a HIV vaccine used in combination with other effective HIV prevention tools in controlling the global HIV epidemic was highlighted, the ongoing HIV vaccine research efforts in Africa was identified, and the gap in continental-initiated HIV vaccine clinical trials noted.

There are diverse perspectives about this. Simon Agwale, the CEO of the Innovative Biotech had a distinct model of vaccine research, development and manufacturing. His organization shall support the research and development process. This will feed into the vaccine manufacturing pipeline of the company. He reported conducting basic research on Ebola vaccine and HIV vaccine development with successes with the development of candidate vaccines to move into clinical trials.

Simon feels strongly about AVMI playing a key role in coordinating HIV vaccine research and research development enterprise in Africa by developing an R&D coordinating entity in the AVMI secretariat. The R&D monitors research with potentials for the development of vaccines. The secretariat can then support the push of products into vaccine production pipeline.

Ebrahim Mohammed of Biovac, a company set up to manufacture vaccines located in South Africa, was also of the same opinion but for a different reason. He feels strongly the AVMI needs to monitor research and development of HIV vaccine and all other ongoing research on vaccine development for diseases of interest to Africa. However, the monitoring of activities in these spaces should be for the development of a healthy ecosystem for vaccine manufacturing and less so for the purpose of coordinating HIV vaccine R&D in Africa.

Unlike Ebrahim, Mwai Ngibuini, from Merck based in Kenya and a participant at the AVMI meeting, felt strongly that AVMI role should not include HIV vaccine R&D coordination as this is a different enterprise outside the sphere of work of AVMI. However, when a vaccine is finally discovered, AVMI role to support its manufacturing in Africa will then be critical. Right now, AVMI should not and cannot focus on HIV vaccine R&D coordination as its mandate does not include R&D.

Patrick Tippoo, the Executive Director of AVMI also shares the views and opinion of Mwai. He is of the opinion that HIV vaccine research is very risky with long timelines and it is not within the mandate of AVMI. Even if one takes an optimistic view about the likelihood of t developing a HIV vaccine, it does not seem like something that will be in the horizon in the next 10 years.

The AVMI should however look forward to engaging more actors and players in the field says Mwai. These include civil society representatives, country level policy makers and other end-users to prevent the organization talking to itself, he says.